158 related articles for article (PubMed ID: 35326662)
1.
Huang YE; Tsai YH; Huang YJ; Lung JH; Ho KW; Yen TC; Chan SC; Chen ST; Tsai MF; Hung MS
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326662
[TBL] [Abstract][Full Text] [Related]
2. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
3. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
5. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
6. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
7. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Value of
Agüloğlu N; Akyol M; Kömek H; Katgı N
Mol Imaging Radionucl Ther; 2022 Jun; 31(2):104-113. PubMed ID: 35770976
[TBL] [Abstract][Full Text] [Related]
9. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
10. Value of interim
Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
[TBL] [Abstract][Full Text] [Related]
11. Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients.
Winther-Larsen A; Fledelius J; Demuth C; Bylov CM; Meldgaard P; Sorensen BS
Transl Oncol; 2016 Dec; 9(6):505-511. PubMed ID: 27816687
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
13. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
Yanarateş A; Yazici B
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):3-8. PubMed ID: 31818695
[TBL] [Abstract][Full Text] [Related]
14. Total lesion glycolysis determined per RECIST 1.1 criteria predicts survival in EGFR mutation-negative patients with advanced lung adenocarcinoma.
Ho TY; Chou PC; Yang CT; Tsang NM; Yen TC
Clin Nucl Med; 2015 Jun; 40(6):e295-9. PubMed ID: 25783515
[TBL] [Abstract][Full Text] [Related]
15. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
Chung HW; Lee KY; Kim HJ; Kim WS; So Y
J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
[TBL] [Abstract][Full Text] [Related]
16. Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using
Kitajima K; Watabe T; Nakajo M; Ishibashi M; Daisaki H; Soeda F; Tanemura A; Kanekura T; Yamazaki N; Ito K
Jpn J Radiol; 2022 Jan; 40(1):75-85. PubMed ID: 34287739
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
18. Does early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer?
Ordu C; Selcuk NA; Erdogan E; Angin G; Gural Z; Memis H; Yencilek E; Dalsuna S; Pilanci K
Medicine (Baltimore); 2014 Dec; 93(28):e299. PubMed ID: 25526475
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
20.
Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
